ReviewPatient related outcome measures2015
Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomes.
Review in Patient related outcome measures, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- RNA N6-methyladenosine-modified-binding protein YTHDF1 promotes prostate cancer progression by regulating androgen function-related gene TRIM68.European journal of medical research · 2023Article
- Role of main RNA modifications in cancer: NSignal transduction and targeted therapy · 2022Review
- Lower Urinary Tract Symptoms in Prostate Cancer Patients Treated With Radiation Therapy: Past and Present.International neurourology journal · 2021Article
- Development and usability testing of the e-EXCELS tool to guide cancer survivorship follow-up care.Psycho-oncology · 2020Article
- Deubiquitinase USP9X regulates the invasion of prostate cancer cells by regulating the ERK pathway and mitochondrial dynamics.Oncology reports · 2019Article
- Eya2 Is Overexpressed in Human Prostate Cancer and Regulates Docetaxel Sensitivity and Mitochondrial Membrane Potential through AKT/Bcl-2 Signaling.BioMed research international · 2019Article
- RNA mOncoTargets and therapy · 2019Article
- Prostate cancer cell proliferation is suppressed by microRNA-3160-5p via targeting of F-box and WD repeat domain containing 8.Oncology letters · 2018Article
- Variation in routine follow-up care after curative treatment for head-and-neck cancer: a population-based study in Ontario.Current oncology (Toronto, Ont.) · 2018Article
- MiR-199a-3p suppresses proliferation and invasion of prostate cancer cells by targeting Smad1.Oncotarget · 2017Article
- MiR-491-5p negatively regulates cell proliferation and motility by targeting PDGFRA in prostate cancer.American journal of cancer research · 2017Article
- Urethral strictures after radiation therapy for prostate cancer.Investigative and clinical urology · 2016Review
- MiR-345 suppresses proliferation, migration and invasion by targeting Smad1 in human prostate cancer.Journal of cancer research and clinical oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundProstate cancer is the most commonly diagnosed cancer in men in the US, and the second most prevalent cancer in men worldwide. High incidence and survival rates for prostate cancer have resulted in a large and growing population of long-term prostate cancer survivors. Long-term follow-up guidelines have only recently been developed to inform approaches to this phase of care for the prostate cancer population.
methodsA PubMed search of English literature through August 2014 was performed. Articles were retrieved and reviewed to confirm their relevance. Patient-reported measures that were used in studies of long-term prostate cancer survivors (ie, at least 2 years posttreatment) were reviewed and included in the review.
resultsA total of 343 abstracts were initially identified from the database search. After abstract review, 105 full-text articles were reviewed of which seven met inclusion criteria. An additional 22 articles were identified from the references of the included articles, and 29 were retained. From the 29 articles, 68 patient-reported outcome measures were identified. The majority (75%) were multi-item scales that had been previously validated in existing literature. We identified four main areas of assessment: 1) physical health; 2) quality of life - general, physical, and psychosocial; 3) health promotion - physical activity, diet, and tobacco cessation; and 4) care quality outcomes.
conclusionThere are a number of well-validated measures that assess patient-reported outcomes that document key aspects of long-term follow-up with respect to patient symptoms and quality of life. However, there are fewer patient-reported outcomes related to health promotion and care quality within the prevention, surveillance, and care coordination components of cancer survivorship. Future research should focus on development of additional patient-centered and patient-related outcomes that enlarge the assessment portfolio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.